Skip to Content
Morningstar

Fortrea Holdings Inc FTRE

Morningstar Rating
Unlock
Stock XNAS Rating as of
$23.35 −0.12 (0.51%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Positive Long-Term Outlook Despite Near-Term Headwinds for Narrow-Moat Fortrea

Rachel Elfman

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. Fortrea has a lengthy, 30-year history dating to the 1990s, originally part of Corning Incorporated's pharmaceutical services business. In 1997, Corning spun off this segment, which was named Covance. In 2015, Laboratory Corporation of America Holdings, or LabCorp, acquired Covance for $6.1 billion.

Read Full Report

Price vs Fair Value

View History
FTRE is trading within a range we consider fairly valued.
Price
$23.35
Fair Value
$31.90
Uncertainty
High
1-Star Price
$23.65
5-Star Price
$29.90
Economic Moat
Qvrbd
Capital Allocation
Rlgjgblf

Bulls Say, Bears Say

Bulls

Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.

Bears

There are potential operational risks associated with Fortrea functioning as a newly independent company post its spinoff from LabCorp.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FTRE is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$23.47
Day Range
$23.08–23.93
52-Week Range
$22.15–41.02
Bid/Ask
$23.35 / $24.69
Market Cap
$2.09 Bil
Volume/Avg
1.5 Mil / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
24.98
Price/Sales
0.69
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
16,000
Website
https://www.fortrea.com

Competitors

Valuation

View More
Metric
FTRE
IQV
MEDP
Price/Earnings (Normalized)
 24.9820.2141.02
Price/Book Value
 1.315.9818.57
Price/Sales
 0.692.566.52
Price/Cash Flow
 69.9716.2336.06
Price/Earnings
FTRE
IQV
MEDP

Financial Strength

Metric
FTRE
IQV
MEDP
Quick Ratio
 1.260.780.72
Current Ratio
 1.470.880.78
Interest Coverage
 0.083.00—
Quick Ratio
FTRE
IQV
MEDP

Profitability

Metric
FTRE
IQV
MEDP
Return on Assets (Normalized)
 −0.91%7.28%21.26%
Return on Equity (Normalized)
 −2.29%31.85%67.47%
Return on Invested Capital (Normalized)
 1.26%12.78%49.10%
Return on Assets
FTRE
IQV
MEDP
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
FkbhqmdqsKrrfm$628.7 Bil
 Vertex Pharmaceuticals Inc
VRTX
HdkvmdrsYzssyy$122.5 Bil
 Regeneron Pharmaceuticals Inc
REGN
XvkkkdxBldcw$114.0 Bil
 Moderna Inc
MRNA
SqqcssrLwqh$45.3 Bil
 Alnylam Pharmaceuticals Inc
ALNY
YsryqcvnNnyqh$31.8 Bil
 argenx SE ADR
ARGX
NxvpqxfcJqgf$25.9 Bil
 BioNTech SE ADR
BNTX
WnpgpkqZzd$19.3 Bil
 Biomarin Pharmaceutical Inc
BMRN
TcyhkbckjThlsfn$15.5 Bil
 United Therapeutics Corp
UTHR
WfqbvppJkzm$14.0 Bil
 Royalty Pharma PLC Class A
RPRX
YvkbcvxmkMndjc$11.6 Bil

Sponsor Center